What Is Insulin Resistance? How It Works, Why It Matters, and How It's Measured

Short Answer

What is insulin resistance? It means your muscle, fat, and liver cells respond less well to insulin — the hormone that helps move glucose out of your blood and into cells for energy. Your body usually tries to solve that problem by asking the pancreas for more insulin. For a while, that extra insulin can keep blood sugar in a normal range, so insulin resistance can be quiet: you may not feel anything even while your metabolism is working harder in the background. (my.clevelandclinic.org)

The problem is capacity. If cells keep resisting insulin's signal, the pancreas has to keep compensating. Over time, it may not be able to keep up; blood sugar can rise, and that is one pathway into prediabetes and type 2 diabetes. So insulin resistance is not the same as diabetes — it is often an upstream state that can exist before diagnostic blood sugar numbers cross into prediabetes or diabetes. (cdc.gov)

It is also not the same as type 1 diabetes. In insulin resistance, your body is still making insulin, but cells do not respond to it well enough. In type 1 diabetes, the immune system destroys insulin-producing cells in the pancreas, so the body makes little or no insulin. (cdc.gov)

Clinicians and researchers do not define insulin resistance from one casual blood-sugar reading. Fasting glucose or A1c can screen for prediabetes and diabetes, but insulin resistance itself is usually estimated from the bigger metabolic picture — for example fasting glucose plus fasting insulin in HOMA-IR, or fasting triglycerides plus glucose in the TyG index. These are surrogate markers, not direct glucose monitoring and not a diagnosis by themselves. Welltory does not measure blood glucose, insulin, or these markers; it tracks signals such as resting heart rate, HRV, sleep, and stress, which can reflect physiological strain but are not a glucose or insulin-resistance test. (my.clevelandclinic.org)

Insulin resistance in one picture

Think of insulin as the signal that helps glucose move out of your blood and into your muscle, fat, and liver cells. When insulin sensitivity is normal, the signal is clear: cells respond, glucose enters, and blood sugar returns toward its usual range after you eat. With insulin resistance, the signal gets weaker. Your cells still hear it, but not well enough, so your pancreas has to push harder by making more insulin. For a while, that extra insulin can keep blood sugar looking "normal." Over time, if the pancreas can't keep up with the resistance, glucose starts to rise — first into prediabetes range, and in some people later into type 2 diabetes. (niddk.nih.gov)

How it's measured (clinician-ordered)

Insulin resistance is usually measured indirectly. The most direct research methods, like clamp studies, are too intensive for everyday care, so clinicians often use fasting blood work plus formulas that estimate how hard your body has to push insulin to keep glucose controlled. These markers can be useful, but they are not the same as a home glucose reading, and they do not all mean the same thing.

The key distinction: HOMA-IR, TyG, and eGDR try to estimate insulin resistance or insulin sensitivity. HbA1c and fasting glucose show what happened downstream to blood sugar. You can have rising insulin resistance before HbA1c or fasting glucose crosses a diagnostic line, because your pancreas may be compensating by making more insulin. That is why clinicians look at the whole pattern: glucose, insulin, triglycerides, waist circumference, blood pressure, medications, medical history, and risk factors — not one number in isolation.

What insulin resistance is — the mechanism

Insulin is a key. After you eat, glucose enters your blood, and insulin helps "unlock" your muscle, liver, and fat cells so glucose can move in and be used for energy or stored for later. That's the simple meaning of insulin resistance: the lock has become harder to open. Your cells still see insulin, but they do not respond to it as well as they should, so the same amount of insulin moves less glucose out of the bloodstream. (niddk.nih.gov)

Your body's first fix is to make more keys. The pancreas releases more insulin to push glucose into cells — a state called hyperinsulinemia. For a while, that extra insulin can keep blood sugar in a healthy range, which is why insulin resistance can build quietly before a routine glucose result looks abnormal. You may feel nothing. But the workload does not disappear: over time, if the pancreas cannot keep making enough insulin to overcome the resistance, blood glucose rises and the pattern can move into prediabetes and then type 2 diabetes. (niddk.nih.gov)

So, if you're asking "what is meant by insulin resistance?" or "what does insulin resistance mean?", the most important idea is this: insulin resistance is upstream of high blood sugar. It is not the same thing as prediabetes or diabetes. Prediabetes means blood glucose is higher than normal but not high enough for type 2 diabetes; insulin resistance is one of the body-level processes that can push glucose in that direction. (niddk.nih.gov)

Because a single glucose reading can miss the early phase, insulin resistance is often estimated indirectly rather than "seen" directly. In routine care, clinicians usually diagnose prediabetes or diabetes with blood glucose-based tests; direct insulin-resistance testing is used mainly in research. But researchers and some clinical settings use calculated surrogate markers to describe insulin resistance and cardiometabolic risk. (niddk.nih.gov)

HOMA-IR is one of the best-known surrogate measures because it combines fasting glucose and fasting insulin into an estimate of how hard the body is working to control glucose. As one long-term cardiovascular study describes it, cardiovascular risk factors, metabolic syndrome, and insulin resistance were assessed and measured "using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)" (Impact of Insulin Resistance and Preclinical Atherosclerosis Parameters in Long-Term Prediction of Cardiovascular Events, 2026). (pmc.ncbi.nlm.nih.gov)

A simpler alternative is gaining use because it relies on lab values many people already have — fasting triglycerides and fasting glucose. One review calls the "triglyceride-glucose (TyG) index a reliable marker of insulin resistance with predictive value for cardiovascular risk" (TyG index variability and cardiovascular mortality, 2026). TyG does not replace a clinician's diagnosis, but it helps explain why insulin resistance is not only about sugar; it is tied to lipid handling, blood vessels, and broader metabolic strain. (pmc.ncbi.nlm.nih.gov)

And another accessible estimate is eGDR, which uses routine clinical variables such as waist circumference, blood pressure or hypertension status, and HbA1c to approximate insulin sensitivity. As one 2026 study puts it, "the estimated glucose disposal rate (eGDR), serving as a measure of insulin resistance (IR), provides a simpler and more accessible method for assessing insulin sensitivity" (eGDR and stroke prevalence and mortality in non-diabetic people, 2026). Lower eGDR generally points toward greater insulin resistance; higher eGDR points toward better insulin sensitivity — the opposite of insulin resistance. (pmc.ncbi.nlm.nih.gov)

What drives it — the common contributors

Insulin resistance usually has more than one driver. Excess fat tissue — especially a larger waist or fat stored around the liver and abdomen — is one of the big ones, because fat tissue is metabolically active. It can send inflammatory signals that make muscle, liver, and fat cells less responsive to insulin: as one 2026 review puts it, "in obesity, chronic low-grade inflammation, marked by immune infiltration and dysregulated adipocyte function, contributes to systemic insulin resistance and metabolic comorbidities" (The Influence of Weight Loss and Weight Regain on Adipose Tissue Inflammation, 2026). NIDDK lists overweight, obesity, or a large waist size among the factors that increase the chance of insulin resistance or prediabetes, and CDC lists overweight or obesity and non-alcoholic fatty liver disease among shared risk factors for prediabetes and type 2 diabetes. (doi.org) (niddk.nih.gov)

Sleep is another lever. When your sleep is short, fragmented, or affected by sleep apnea, your body has more trouble coordinating hormones that regulate appetite, stress chemistry, inflammation, glucose output from the liver, and how strongly cells respond to insulin. As one 2026 review describes, "sleep disorders affect hormone production and secretion, which lead to endocrine changes, including impaired glucose tolerance, decreased insulin sensitivity, hepatic steatosis, and increased inflammatory responses" (Sleep disorders impact hormonal regulation, 2026). NIDDK specifically includes sleep apnea among conditions linked with higher chances of insulin resistance or prediabetes, and it includes getting enough sleep as part of a healthy-living approach to prevention or reversal. (pmc.ncbi.nlm.nih.gov) (niddk.nih.gov)

Hormones matter, too. Insulin resistance often clusters with endocrine conditions — most notably PCOS, where reproductive hormones, inflammation, oxidative stress, and insulin signaling can all overlap: one 2026 paper describes "polycystic ovary syndrome (PCOS)" as "a heterogeneous endocrine-metabolic disorder in which reproductive dysfunction coexists with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress (OS)" (Redox-endocrine triad in PCOS, 2026). NIDDK also names Cushing's syndrome and acromegaly as conditions that can raise the chance of insulin resistance or prediabetes. (doi.org) (niddk.nih.gov)

The rest of the contributor list is broader: not being physically active, family history, aging, smoking or secondhand smoke exposure, and some long-term medications, including glucocorticoids, some antipsychotics, and some medicines used for HIV. Pregnancy deserves a special note: insulin resistance normally rises during pregnancy to help route nutrients to the growing fetus, but if the pancreas cannot compensate with enough insulin, blood glucose can rise into gestational diabetes. NIDDK and CDC both flag a history of gestational diabetes as a later risk factor for prediabetes or type 2 diabetes. (niddk.nih.gov)

Why it matters — where insulin resistance leads

Insulin resistance matters because it often starts before blood sugar crosses a lab threshold. At first, your pancreas can compensate by making more insulin. That can keep glucose looking "normal" for a while, but it comes at a cost: your cells are still pushing back against insulin's signal, your pancreas is working harder, and over time that backup system can wear down. This is the pathway that sets the stage for prediabetes and type 2 diabetes. (cdc.gov)

Insulin resistance is closely tied to the development of type 2 diabetes, and the transition is measurable. In one large long-term cohort, "of the 60% of adults with prediabetes at baseline, ~30% progressed to diabetes (median time to diabetes, 7 years)" (Prediabetes is associated with elevated risk of clinical outcomes even without progression to diabetes, 2025). Even at the prediabetes stage the risk is real: in the same cohort, prediabetes — defined as "HbA1c 39-47 mmol/mol [5.7-6.4%] or fasting glucose 5.6-6.9 mmol/l" — was "associated with elevated risks of microvascular and macrovascular complications." (pmc.ncbi.nlm.nih.gov)

That is why "just insulin resistance" is worth taking seriously. It is not diabetes yet, and it is not a diagnosis Welltory can make for you. But it can be the earlier, more modifiable stage — the point where your body is asking for less strain, better insulin sensitivity, and clinician-ordered testing if your risk is high. The earlier you catch the pattern, the more room you usually have to change the trajectory before glucose thresholds are crossed. (cdc.gov)

Insulin resistance vs prediabetes vs diabetes — the numbers

These are different points on the same metabolic continuum, but they are not diagnosed the same way. Insulin resistance can start while your blood sugar is still in the "normal" range because your pancreas is working harder and releasing more insulin to keep glucose under control. Prediabetes and diabetes are later points on that path, defined by clinician-ordered blood tests. The ADA Standards of Care in Diabetes—2026 list the current diagnostic cutoffs for prediabetes and diabetes, and note that, unless high blood sugar is unequivocal, diagnosis usually requires confirmation with repeat abnormal testing. (pmc.ncbi.nlm.nih.gov)

• Insulin resistance — your muscle, fat, and liver cells respond poorly to insulin, so glucose does not move from blood into cells as efficiently. Blood sugar can still look healthy if your pancreas can compensate by making more insulin. There is no single ADA glucose cutoff for "insulin resistance" itself; in practice and research, it may be estimated with surrogate markers such as HOMA-IR or TyG, while NIDDK notes that testing for insulin resistance is used primarily in research rather than routine diagnosis. (niddk.nih.gov)

• Prediabetes — blood sugar is higher than normal but not high enough for diabetes. The ADA Standards of Care—2026 define prediabetes as A1C 5.7–6.4% (39–47 mmol/mol), fasting plasma glucose 100–125 mg/dL (5.6–6.9 mmol/L), or 2-hour OGTT glucose 140–199 mg/dL (7.8–11.0 mmol/L). In the research wording used in one long-term cohort, prediabetes is described as "HbA1c 39-47 mmol/mol [5.7-6.4%] or fasting glucose 5.6-6.9 mmol/l." (pmc.ncbi.nlm.nih.gov)

• Type 2 diabetes — blood sugar has crossed the diabetes diagnostic range, commonly because insulin resistance has become too strong for pancreatic compensation to keep glucose down. The ADA Standards of Care—2026 define diabetes in nonpregnant people as A1C ≥6.5% (≥48 mmol/mol), fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L), 2-hour OGTT glucose ≥200 mg/dL (≥11.1 mmol/L), or random plasma glucose ≥200 mg/dL with classic symptoms or hyperglycemic crisis. In research cohorts, diabetes may also be operationalized by medication use, as in one study that defined it by "fasting blood glucose level ≥126 mg/dL, glycated hemoglobin level ≥6.5%, or self-reported initiation of glucose-lowering medications" (Aichi Worker's Cohort Study, 2026). (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)

Is insulin resistance the same as diabetes? And type 1?

No. Insulin resistance is a body state; diabetes is a diagnosis. You can be insulin resistant while your blood sugar is still in the normal range because your pancreas may be working harder and releasing extra insulin to keep glucose under control. Diabetes is diagnosed when blood-glucose markers cross clinical thresholds — for example, an A1C of 6.5% or higher, fasting plasma glucose of 126 mg/dL or higher, or a 2-hour oral glucose tolerance result of 200 mg/dL or higher, usually confirmed with repeat testing when symptoms are not clear. Prediabetes sits in between: blood sugar is higher than normal, but not yet in the diabetes range. (niddk.nih.gov) (diabetes.org)

Type 1 is a different pathway. Type 1 diabetes is not caused by insulin resistance; it is an autoimmune disease in which the immune system destroys the pancreatic cells that make insulin. The core problem is too little insulin, not cells "ignoring" insulin. Most people with type 1 need insulin every day to manage blood glucose and stay alive. Lifestyle habits can support overall health and glucose management, but they do not cause type 1 diabetes and cannot reverse the autoimmune loss of insulin-producing cells. (niddk.nih.gov)

The confusing part: a person with type 1 can also become insulin resistant — for example, with weight gain, puberty, pregnancy, steroid medication, smoking, or other stressors on metabolism. That does not make type 1 "the same as" type 2. It means two problems can overlap: autoimmune insulin deficiency plus reduced insulin sensitivity. When people talk about improving or "reversing" insulin resistance, they usually mean the prediabetes/type 2 pathway, where making the body more insulin-sensitive can help prevent or delay type 2 diabetes and may improve glucose control. (diabetes.org)

Can it be improved?

Often, yes — and the markers can move because insulin resistance is not a fixed trait. When your muscles use more glucose, your liver releases less extra glucose, visceral fat and inflammation ease, and your pancreas does not have to push out as much insulin to get the same job done. In one intensive lifestyle program for people with type 2 diabetes, the group that reached remission had larger improvements than the group that did not: it "showed significantly greater improvements in weight (-8.5% vs. -5.2%), BMI (-8.6% vs. -5.2%), HbA1c (-15.3% vs. -12.4%), fasting insulin (-26.6% vs. -11.4%), and homeostatic model assessment of insulin resistance (HOMA-IR) (-37.3% vs. -19.7%), than the non-remission group (p <0.05)" (Type 2 diabetes remission in an Indian cohort, 2026). That does not mean everyone gets remission, or that insulin resistance is solved by willpower. It means the biology can respond. (pmc.ncbi.nlm.nih.gov)

If you're asking what is good for insulin resistance, the boring answer is also the most powerful one: weight loss when needed, regular movement, sleep, stress management, and a dietary pattern you can keep doing. Physical activity makes your body more sensitive to insulin; weight loss can reduce the strain that drives insulin resistance; balanced eating patterns and enough sleep support the same direction. Diet pattern matters, too: one review notes that "Mediterranean dietary interventions reduce hs-CRP by 18-32%, increase microbiome diversity by 6-28%, and improve metabolic markers including HOMA-IR and TG/HDL ratios" (A Conceptual Digital Health Framework for Longevity Optimization, 2026). For many people, the best way to reduce insulin resistance is not a cleanse or a single "insulin resistance food." It is building repeatable meals, muscle work, walking, recovery, and sleep into ordinary weeks. (pmc.ncbi.nlm.nih.gov) (cdc.gov)

Medication is different from lifestyle. Metformin and other glucose-lowering medicines are prescription treatments, not self-experiments. In some situations, a clinician may use them to improve insulin sensitivity or lower glucose-related risk — one 2026 review notes that "beyond its direct impact on glucose metabolism, metformin also improves insulin sensitivity and has beneficial effects on lipid profiles" (From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin, 2026). Whether a medicine is appropriate, which medicine fits, and the dose are medical decisions made by a clinician based on your labs, diagnosis, kidney function, other medications, pregnancy status, side effects, and overall risk. This article gives no doses. (pmc.ncbi.nlm.nih.gov)

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data